Effectiveness of oral glutathione in reducing nitric oxide and IL-1α concentrations for clinical improvement in mild to moderate acne vulgaris: a randomized controlled trial.

IF 1 Q4 DERMATOLOGY
Ferra Olivia Mawu, Anis Irawan Anwar, Khairuddin Djawad, Agussalim Bukhari, Marlyn Grace Kapantow, Paulus Mario Christopher
{"title":"Effectiveness of oral glutathione in reducing nitric oxide and IL-1α concentrations for clinical improvement in mild to moderate acne vulgaris: a randomized controlled trial.","authors":"Ferra Olivia Mawu, Anis Irawan Anwar, Khairuddin Djawad, Agussalim Bukhari, Marlyn Grace Kapantow, Paulus Mario Christopher","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Acne vulgaris (AV) is a chronic inflammatory dermatosis predominantly affecting adolescents and young adults. Oxidative and nitrosative stress, marked by elevated nitric oxide (NO) and interleukin (IL)-1α, contributes to AV pathogenesis. Glutathione, a key antioxidant, may attenuate oxidative and nitrosative stress and modulate inflammatory pathways. This study investigates the effectiveness of oral glutathione supplementation on serum NO and IL-1α concentrations, and clinical improvement in mild to moderate AV patients.</p><p><strong>Methods: </strong>A randomized controlled trial was conducted involving 40 subjects diagnosed with mild to moderate AV. Participants were randomized to receive either 500 mg oral glutathione (n = 22) or placebo (n = 18) once daily for 4 weeks. Clinical severity of AV was assessed utilizing the Lehmann criteria. Serum levels of NO and IL-1α were measured at baseline and week 4.</p><p><strong>Results: </strong>At week 4, reductions in serum NO and IL-1α concentrations were observed in the glutathione group; however, these changes did not reach statistical significance (p > 0.05). Clinical improvement occurred in seven subjects (31.8%) in the glutathione group, with a reduction from moderate to mild severity. No adverse reactions were reported.</p><p><strong>Conclusions: </strong>Oral glutathione supplementation demonstrated a non-significant trend toward reducing oxidative and nitrosative stress markers and improving mild to moderate AV. Further studies are recommended to validate these findings.</p>","PeriodicalId":45914,"journal":{"name":"Acta Dermatovenerologica Alpina Pannonica et Adriatica","volume":"34 3","pages":"95-99"},"PeriodicalIF":1.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Dermatovenerologica Alpina Pannonica et Adriatica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Acne vulgaris (AV) is a chronic inflammatory dermatosis predominantly affecting adolescents and young adults. Oxidative and nitrosative stress, marked by elevated nitric oxide (NO) and interleukin (IL)-1α, contributes to AV pathogenesis. Glutathione, a key antioxidant, may attenuate oxidative and nitrosative stress and modulate inflammatory pathways. This study investigates the effectiveness of oral glutathione supplementation on serum NO and IL-1α concentrations, and clinical improvement in mild to moderate AV patients.

Methods: A randomized controlled trial was conducted involving 40 subjects diagnosed with mild to moderate AV. Participants were randomized to receive either 500 mg oral glutathione (n = 22) or placebo (n = 18) once daily for 4 weeks. Clinical severity of AV was assessed utilizing the Lehmann criteria. Serum levels of NO and IL-1α were measured at baseline and week 4.

Results: At week 4, reductions in serum NO and IL-1α concentrations were observed in the glutathione group; however, these changes did not reach statistical significance (p > 0.05). Clinical improvement occurred in seven subjects (31.8%) in the glutathione group, with a reduction from moderate to mild severity. No adverse reactions were reported.

Conclusions: Oral glutathione supplementation demonstrated a non-significant trend toward reducing oxidative and nitrosative stress markers and improving mild to moderate AV. Further studies are recommended to validate these findings.

口服谷胱甘肽降低一氧化氮和IL-1α浓度对轻度至中度寻常痤疮临床改善的有效性:一项随机对照试验
寻常痤疮(AV)是一种慢性炎症性皮肤病,主要影响青少年和年轻人。以一氧化氮(NO)和白细胞介素(IL)-1α升高为标志的氧化应激和亚硝化应激有助于AV的发病。谷胱甘肽是一种重要的抗氧化剂,可以减轻氧化应激和亚硝化应激,调节炎症途径。本研究探讨口服谷胱甘肽对轻中度AV患者血清NO和IL-1α浓度的影响及临床改善情况。方法:进行了一项随机对照试验,涉及40名诊断为轻中度AV的受试者。参与者随机接受500 mg口服谷胱甘肽(n = 22)或安慰剂(n = 18),每天一次,持续4周。采用Lehmann标准评估AV的临床严重程度。在基线和第4周测定血清NO和IL-1α水平。结果:第4周,谷胱甘肽组小鼠血清NO、IL-1α浓度降低;但差异无统计学意义(p < 0.05)。谷胱甘肽组有7名受试者(31.8%)出现临床改善,严重程度从中度降至轻度。无不良反应报告。结论:口服谷胱甘肽补充剂在降低氧化和亚硝化应激标志物以及改善轻度至中度AV方面表现出不显著的趋势。建议进一步研究来验证这些发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.70
自引率
8.30%
发文量
38
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信